Nutex Health Gestione
Criteri Gestione verificati 3/4
Nutex Health Il CEO è Tom Vo, nominato in Apr2022, e ha un mandato di 4.25 anni. la retribuzione annua totale è $ 2.20M, composta da 45.5% di stipendio e 54.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 30.56% delle azioni della società, per un valore di $ 312.32M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.2 anni e 4.3 anni.
Informazioni chiave
Tom Vo
Amministratore delegato
US$2.2m
Compenso totale
| Percentuale dello stipendio del CEO | 45.51% |
| Mandato del CEO | 4.3yrs |
| Proprietà del CEO | 30.6% |
| Durata media del management | 4.2yrs |
| Durata media del Consiglio di amministrazione | 4.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento narrativa • Jun 22
NUTX: Low EV EBITDA Multiple And Buyback Activity Will Support Future Upside
Analysts nudged their Nutex Health price target to $235, pointing to what they view as a low ~3x EV/EBITDA multiple, limited existing coverage, and ongoing investor confusion around the No Surprises Act as key factors behind their valuation work. What’s in the News for Nutex Health Nutex Health reported completing a share repurchase tranche between March 5, 2026 and March 31, 2026, buying 21,086 shares, or 0.3% of outstanding shares, for a total of US$3.02 million under the buyback announced on March 5, 2026.Aggiornamento narrativa • Jun 04
NUTX: Low EV EBITDA Multiple Will Support Future Upside Potential
Analysts have raised their Nutex Health fair value estimate from $221.67 to $235.50, citing what they describe as a relatively low ~3x EV/EBITDA multiple and limited prior coverage of the stock as key reasons for the higher $235 price target. What's in the News No recent company specific news, periodical coverage, or key developments were identified in the provided sources for Nutex Health.
Aggiornamento narrativa • May 09
NUTX: Share Repurchases Will Support Future Margins And Upside Potential
Analysts now place Nutex Health's fair value at $175.00, up from $150.00, citing updated assumptions around revenue growth of 5.25%, a profit margin of 21.15%, a discount rate of 7.19% and a forward P/E of 7.95. What's in the News On March 5, 2026, the Board of Directors authorized a share buyback plan for Nutex Health.Aggiornamento narrativa • Apr 23
NUTX: Share Repurchases Will Support Future Margins And Undervalued Upside
Analysts reaffirm a $150.00 price target for Nutex Health, citing updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a small change in future P/E multiples as key inputs to their valuation work. What's in the News Nutex Health Inc.Aggiornamento narrativa • Apr 09
NUTX: New Buyback Program Will Support Future Margin Resilience
Analysts have raised their Nutex Health price target to $150.00 as they now factor in slightly stronger revenue growth, a modestly higher profit margin of about 18.6%, and a marginally lower future P/E assumption near 8x. What's in the News From October 1, 2025 to December 31, 2025, Nutex Health repurchased 27,870 shares, about 0.4% of its stock, for US$4.95 million under a previously announced buyback program (Key Developments).Aggiornamento narrativa • Mar 25
NUTX: Share Repurchases Will Support Future Upside Potential
Analysts have adjusted their price target on Nutex Health from $241.67 to $221.67, reflecting updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Nutex Health completed a previously announced buyback program, repurchasing 27,870 shares, representing 0.4% of the company, for a total of $4.95 million between October 1, 2025 and December 31, 2025 (Key Developments).Aggiornamento narrativa • Mar 11
NUTX: New Hospitals And Buybacks Will Support Future Margin Resilience
Analysts have adjusted their price target on Nutex Health to $150 from $220, citing updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Nutex Health Inc.Aggiornamento narrativa • Feb 25
NUTX: Expanded Hospital Footprint Will Support Future Margin Resilience
Analysts have kept their $220.00 price target for Nutex Health unchanged, citing relatively steady assumptions for the discount rate, long-term revenue growth, profit margin, and future P/E expectations. What's in the News Nutex Health announced the opening of its 26th hospital, Archview ER & Hospital, in a new state, Missouri, expanding its footprint into St. Louis for the first time (Key Developments).Aggiornamento narrativa • Feb 11
NUTX: Future Margin Resilience Will Outlast Fraud Allegations And Filing Delay
Analysts have maintained their Nutex Health fair value estimate at $220.00. They cite small adjustments to the discount rate, revenue growth, profit margin, and expected future P/E assumptions, rather than any major change in their overall view.Aggiornamento narrativa • Jan 27
NUTX: Future Margin Strength Will Outweigh Fraud Allegation And Filing Risk
Analysts have kept their price target on Nutex Health steady at US$220.00, citing slightly higher modeled revenue growth, a modestly improved profit margin and a marginally lower forward P/E assumption as key reasons for maintaining their view. What's in the News Short seller Capybara Research published a report alleging that Nutex Health and its founder CEO engaged in fraudulent and unethical business practices, citing interviews with former insiders and partners and claiming a pattern of misconduct over about 10 years (Periodical).Aggiornamento narrativa • Jan 12
NUTX: Future Margin Strength Will Offset Fraud Allegation Headwinds
Analysts have slightly revised their price target on Nutex Health to US$220, reflecting modestly updated assumptions around revenue, profit margins, and future P/E expectations. What's in the News Capybara Research published a report alleging Nutex Health and its CEO engaged in fraudulent and unethical business practices over a period of about 10 years.Aggiornamento narrativa • Dec 26
NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations
Analysts have modestly raised their price target on Nutex Health to approximately 220 dollars per share, citing slightly stronger anticipated revenue growth and profit margins. These factors support a marginally lower future price to earnings multiple.Aggiornamento narrativa • Dec 12
NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations
Narrative Update on Nutex Health Analysts have raised their price target on Nutex Health from 205.00 dollars to 220.00 dollars, reflecting expectations for meaningfully improved profit margins and a more favorable future earnings multiple, despite moderating revenue growth assumptions and a slightly lower discount rate. What's in the News Capybara Research issued a report alleging Nutex Health and its CEO engaged in a long running pattern of fraudulent and unethical business practices, and warned that more physician groups and emergency rooms may sever ties with the company (Capybara Research report).Seeking Alpha • Sep 10
Nutex: Diagnosed With A Case Of Fair Value
Summary Nutex Health shows strong revenue growth and a healthy balance sheet, but recent issues with SEC filings and a short report caused the stock to decline. Growth prospects hinge on the execution of expansion, especially in the IPA segment, which could drive future cash flow at low cost. Competitive pressures, cyclical capex, and significant stock-based compensation limit upside and warrant a deeper margin of safety for investors. At current levels, NUTX is not undervalued; I recommend a Hold rating and would only consider buying below $65 for better risk-reward. Read the full article on Seeking AlphaNuova narrativa • May 28
Aging US Population Will Drive Micro-Hospital Expansion Despite Payer Challenges
Expansion in key markets and value-focused care models align Nutex with demographic trends and rising demand for accessible, cost-effective healthcare.Articolo di analisi • Jan 24
Health Check: How Prudently Does Nutex Health (NASDAQ:NUTX) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Dec 25
Nutex Health Inc. (NASDAQ:NUTX) Might Not Be As Mispriced As It Looks
When close to half the companies operating in the Healthcare industry in the United States have price-to-sales ratios...Articolo di analisi • Aug 12
Nutex Health Inc. (NASDAQ:NUTX) Just Reported, And Analysts Assigned A US$2.75 Price Target
The analysts might have been a bit too bullish on Nutex Health Inc. ( NASDAQ:NUTX ), given that the company fell short...Articolo di analisi • Apr 17
Nutex Health Inc.'s (NASDAQ:NUTX) 30% Cheaper Price Remains In Tune With Revenues
Unfortunately for some shareholders, the Nutex Health Inc. ( NASDAQ:NUTX ) share price has dived 30% in the last thirty...Seeking Alpha • Aug 23
Nutex Health GAAP EPS of -$0.03, revenue of $58.05M
Nutex Health press release (NASDAQ:NUTX): Q2 GAAP EPS of -$0.03. Revenue of $58.05M (-7.6% Y/Y). Adjusted EBITDA of $9.4M. As of June 30, 2022, the company had total assets of $871.8M, including cash and cash equivalents of $47.6M.Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$96m |
| Dec 31 2025 | US$2m | US$1m | US$71m |
| Sep 30 2025 | n/a | n/a | US$121m |
| Jun 30 2025 | n/a | n/a | US$56m |
| Mar 31 2025 | n/a | n/a | US$74m |
| Dec 31 2024 | US$662k | US$558k | US$52m |
| Sep 30 2024 | n/a | n/a | -US$41m |
| Jun 30 2024 | n/a | n/a | -US$38m |
| Mar 31 2024 | n/a | n/a | -US$41m |
| Dec 31 2023 | US$1m | US$1m | -US$46m |
| Sep 30 2023 | n/a | n/a | -US$29m |
| Jun 30 2023 | n/a | n/a | -US$436m |
| Mar 31 2023 | n/a | n/a | -US$451m |
| Dec 31 2022 | US$938k | US$932k | -US$425m |
| Sep 30 2022 | n/a | n/a | -US$396m |
| Jun 30 2022 | n/a | n/a | US$70m |
| Mar 31 2022 | n/a | n/a | US$122m |
| Dec 31 2021 | US$258k | US$251k | US$133m |
| Sep 30 2021 | n/a | n/a | US$159m |
| Dec 31 2020 | US$159k | US$151k | US$106m |
Compensazione vs Mercato: La retribuzione totale di Tom ($USD 2.20M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.63M ).
Compensazione vs guadagni: La retribuzione di Tom è aumentata di oltre il 20% nell'ultimo anno.
AMMINISTRATORE DELEGATO
Tom Vo (53 yo)
4.3yrs
Mandato
US$2,197,420
Compensazione
Dr. Thomas T. Vo, also known as Tom, M.D., MBA, is Chairman of the Board and Chief Executive Officer of Nutex Health, Inc. from April 1, 2022. Dr. Vo joined the Nutex Health, Inc. in April 1, 2022. He is t...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman of the Board & CEO | 4.3yrs | US$2.20m | 30.56% $ 312.3m | |
| President & Director | 4.3yrs | US$1.71m | 0.11% $ 1.2m | |
| Chief Financial Officer | 4.1yrs | US$924.21k | 0.12% $ 1.2m | |
| Chief Operating Officer | less than a year | US$392.72k | Nessun dato | |
| Chief Medical Officer | 4.3yrs | US$716.59k | 1.2% $ 12.2m | |
| Investor & Public Relations Manager | 1.3yrs | Nessun dato | Nessun dato | |
| Director of Compliance | 3yrs | Nessun dato | Nessun dato | |
| Director of Marketing | no data | Nessun dato | Nessun dato | |
| Director of Human Resources | 4.5yrs | Nessun dato | Nessun dato | |
| Chief Legal Officer & Board Secretary of SEC | 4.3yrs | US$593.32k | 0.034% $ 352.0k | |
| Chief Legal Officer of Healthcare & Board Secretary | no data | US$275.36k | 0.040% $ 409.6k | |
| Director of Treasury | 1.3yrs | Nessun dato | Nessun dato |
4.2yrs
Durata media
54.5yo
Età media
Gestione esperta: Il team dirigenziale di NUTX è considerato esperto (durata media dell'incarico 4.2 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman of the Board & CEO | 4.3yrs | US$2.20m | 30.56% $ 312.3m | |
| President & Director | 4.3yrs | US$1.71m | 0.11% $ 1.2m | |
| Independent Director | 2.3yrs | US$268.35k | 0% $ 0 | |
| Independent Director | 1yr | US$152.27k | 0.0022% $ 22.3k | |
| Lead Independent Director | 4.3yrs | US$277.61k | Nessun dato | |
| Independent Director | 4.3yrs | US$271.87k | 0.00097% $ 9.9k | |
| Director | 2.3yrs | Nessun dato | 0.50% $ 5.1m |
4.3yrs
Durata media
65yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NUTX sono considerati esperti (durata media dell'incarico 4.3 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/29 02:10 |
| Prezzo dell'azione a fine giornata | 2026/07/28 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Nutex Health Inc. è coperta da 6 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| William Sutherland | Benchmark Company |
| Anderson Schock | B. Riley Securities, Inc. |
| Eugene Mannheimer | Freedom Capital Markets |